期刊文献+

唑来膦酸致严重低血钙、低血钾1例并文献复习 被引量:3

One case of hypocalcemia and hypokalemia induced by zoledronic acid and literature review
下载PDF
导出
摘要 1例24岁女性患者确诊为原发性甲状旁腺功能亢进,甲状旁腺腺瘤,入院因血钙偏高给予唑来膦酸注射液5 mg,一次,静脉滴注,用药后22 h患者出现了肌肉酸痛、四肢麻木、手足抽搐,伴呼吸困难,查体:面神经叩击试验及束臂加压试验阳性,急查血钙2.05 mmol·L^(-1),血钾3.41 mmol·L^(-1)。用药第3天,血钙最低为1.47 mmol·L^(-1),血清白蛋白正常,用药第4天血钾最低为2.79 mmol·L^(-1),给予补钙、补钾等对症处理,用药第5天,患者查体面神经叩击试验及束臂加压试验阴性。用药第6天,患者复查血钙2.30 mmol·L^(-1),血钾2.99 mmol·L^(-1),血钾血钙均有所好转,转入普外科行手术治疗。 One case of 24-year-old female patient diagnosed as priamry hyperparathyroidism and parathyroid gland adenoma.After admission to hospital,the patient was administrated zoledronic acid injection 5 mg once intravenously because of high blood calcium.22 hours after administration,the patient had a muscular soreness,numbness of limbs,tetany,dyspnea,the facial nerve taps test and beam arm pressure test was positive,the blood calcium 2.05 mmol·L-1,potassium 3.41 mmol·L-1,hypocalcemia and hypokalemia gradually increased.3 days after administration,the minimum serum calcium was 1.47 mmol·L-1,serum albumin was normal.4 days after administration,the minimum serum potassium was 2.79 mmol·L-1.The patients was given calcium,potassium and other symptomatic treatment.5 days after administration,the body facial nerve taps test and beam arm pressure test were negative.6 days after administration,the result of recheck showed the serum calcium was 2.30 mmol·L-1,the serum potassium was 2.99 mmol·L-1,obviously improved.The patient was transferred to general surgery department for surgical treatment.
作者 李久旭 汤智慧 LI Jiu-xu;TANG Zhi-hui(Department of Pharmacy,Chinese PLA General Hospital,Beijing 100853,China)
出处 《中国药物应用与监测》 CAS 2018年第2期123-126,共4页 Chinese Journal of Drug Application and Monitoring
基金 解放军总医院临床科研扶持基金项目(2015FCCXYY-2002)
关键词 原发性甲状旁腺功能亢进症 唑来膦酸 低血钙 低血钾 药品不良反应 Priamry hyperparathyroidism Zoledronic acid Hypocalcemia Hypokalemia Adverse drug reaction
  • 相关文献

参考文献7

二级参考文献87

  • 1崔巍,彭六保.唑来膦酸的临床应用研究进展[J].中南药学,2006,4(6):467-469. 被引量:19
  • 2王鸥,邢小平,孟迅吾,余卫,夏维波,李梅,刘怀成,胡莹莹,姜艳,韩桂艳.原发性甲状旁腺功能亢进症患者骨密度及胫骨超声速率的改变[J].诊断学理论与实践,2006,5(6):499-502. 被引量:3
  • 3Conte P, Coleman R. Bisphosphonates ha the treatment of skeletal metastases[J]. Semin Oncol, 2004, 31(5 Suppl 10): 59~63.
  • 4Cameron D. Proven efficacy of zoledron acid in the treatment of bone metastases in patients with breast cancer and other malignancies[J]. Breast, 2003, 12 Supple 2:S22~S29.
  • 5Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases [J]. Semin Oncol. 2001, 28(2 Suppl 6): 11~16.
  • 6Quint LE, Tummala S, Brisson LJ. et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer[J]. Ann Thorac Surg, 1996, 62(1): 246~250.
  • 7Coleman RE. Bisphosphonates: clinical experience [J]. Oncologist, 2004, 9 Suppl 4:14~27.
  • 8Berenson JR, Rosen LS, Howell A. et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases [J]. Cancer, 2001, 91(7): 1191~1200.
  • 9Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the trealanent of hypercalcemia of malignancy: apooled analysis of two randomized, controlled clinical trials [J]. J Clin Oncol,2001, 19(2): 558~567.
  • 10Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolyfic lesions of multiple myeloma: a phase Ⅲ, double-blind, comparative trial[J]. Cancer J, 2001, 7(5): 377~387.

共引文献28

同被引文献19

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部